The biological effects of castration on prostate cancers will be studies by administration of degarelix prior to radical prostatectomy. The effects will be studied by analysis of gene expression and immunohistochemistry focusing on markers of proliferation and apoptosis of samples taken at the time of radical prostatectomy (7 days after administration of degarelix). Tumours from patients treated with neo-adjuvant degarelix will be compared with tumours from patients who have not been medically castrated.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
40
7 days prior to radical prostatectomy the patient will have a subcutaneous injection of 240mg degarelix.
Cambridge University Hopital NHS Trust
Cambridge, Cambridgeshire, United Kingdom
RECRUITINGproliferative index defined by immunohistochemistry for ki67
Time frame: at surgery, 7 days after administration of degarelix
Gene expression levels measured by microarray
Time frame: At surgery 7 days after degarelix administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.